Liraglutide is under clinical development by Novo Nordisk and currently in Phase II for Pouchitis. According to GlobalData, Phase II drugs for Pouchitis does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Liraglutide LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Liraglutide overview
Liraglutide (Victoza) is a potent anti-diabetic agent. It is the first and only human GLP-1 analog drug, synthesized by recombinant DNA expression in the species saccharomyces cerevisiae and has been engineered bio-technologically to be about 97 percent homologous to the Glucagon like peptide 1 (GLP-1) expressed in the humans through the substitution of lysine at 34th position with arginine. It is formulated as solution for subcutaneous route of administration and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and to reduce the risk of major adverse cardiovascular events (cardiovascular death, non- fatal myocardial infarction, or non- fatal stroke) in adults with type 2 diabetes mellitus, established cardiovascular disease and indicated for the treatment of pediatric patients of 10 years or older with type 2 diabetes.
Liraglutide is under development for the treatment of obesity, ileal pouch-anal anastomosis, Parkinson's disease. It was also under development for non-alcoholic steatohepatitis, psoriatic arthritis and also as an adjunct therapy to insulin in Type 1 diabetes.
Novo Nordisk overview
Novo Nordisk, a subsidiary of Novo Holdings AS, is a healthcare company focused on discovering, developing, and manufacturing innovative biological medicines. It focuses on advancing drugs for the treatment of diabetes and other serious chronic conditions, including hemophilia, human growth hormone (HGH) disorders, rare blood and rare endocrine diseases, and obesity. The company’s portfolio includes pre-filled delivery systems for insulin; glucagon hypokit; cartridge; needles; vials; insulin; estradiol for hormone replacement; recombinant drugs for hemophilia; glucagon; and oral antidiabetic agents. The company markets its products through subsidiaries in North America, Europe, Asia, Latin America, Africa, the Middle East and Australia. Novo Nordisk is headquartered in Bagsvaerd, Denmark.
For a complete picture of Liraglutide’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
